What is Litfulo and what is it used for?

Litfulo is used to treat severe alopecia areata in adults and adolescents 12 years of age and older. Alopecia areata is a condition where the body’s own immune system attacks hair follicles, causing inflammation that leads to hair loss on the scalp, face and/or other parts of the body. Litfulo works by reducing the activity of enzymes which are involved in inflammation at the hair follicle, leading to hair regrowth in patients with alopecia areata.

Reference Information

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Litfulo in Great Britain these can be found at the electronic Medicines Compendium (eMC).

This medicine can only be obtained with a prescription.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.